vs
EDGEWELL PERSONAL CARE Co（EPC）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
EDGEWELL PERSONAL CARE Co的季度营收约是Orthofix Medical Inc.的1.9倍（$422.8M vs $219.9M），Orthofix Medical Inc.净利率更高（-1.0% vs -15.5%，领先14.5%），Orthofix Medical Inc.同比增速更快（2.0% vs -11.6%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-137.5M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -16.0%）
Edgewell个人护理是一家总部位于美国康涅狄格州谢尔顿的跨国消费品企业，主营业务聚焦个人护理产品领域。公司在2015年从劲量控股分拆后正式成立，目前在全球多个市场开展个人护理相关业务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
EPC vs OFIX — 直观对比
营收规模更大
EPC
是对方的1.9倍
$219.9M
营收增速更快
OFIX
高出13.6%
-11.6%
净利率更高
OFIX
高出14.5%
-15.5%
自由现金流更多
OFIX
多$154.3M
$-137.5M
两年增速更快
OFIX
近两年复合增速
-16.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $422.8M | $219.9M |
| 净利润 | $-65.7M | $-2.2M |
| 毛利率 | 38.1% | 71.1% |
| 营业利润率 | -4.5% | 0.2% |
| 净利率 | -15.5% | -1.0% |
| 营收同比 | -11.6% | 2.0% |
| 净利润同比 | -3028.6% | 92.4% |
| 每股收益（稀释后） | $-1.41 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EPCOFIX
| Q4 25 | $422.8M | $219.9M | ||
| Q3 25 | $600.5M | $205.6M | ||
| Q2 25 | $627.2M | $203.1M | ||
| Q1 25 | $580.7M | $193.6M | ||
| Q4 24 | $415.1M | $215.7M | ||
| Q3 24 | $517.6M | $196.6M | ||
| Q2 24 | $647.8M | $198.6M | ||
| Q1 24 | $599.4M | $188.6M |
净利润EPCOFIX
| Q4 25 | $-65.7M | $-2.2M | ||
| Q3 25 | $-30.6M | $-22.8M | ||
| Q2 25 | $29.1M | $-14.1M | ||
| Q1 25 | $29.0M | $-53.1M | ||
| Q4 24 | $-2.1M | $-29.1M | ||
| Q3 24 | $8.8M | $-27.4M | ||
| Q2 24 | $49.0M | $-33.4M | ||
| Q1 24 | $36.0M | $-36.0M |
毛利率EPCOFIX
| Q4 25 | 38.1% | 71.1% | ||
| Q3 25 | 37.9% | 72.2% | ||
| Q2 25 | 42.8% | 68.7% | ||
| Q1 25 | 44.1% | 62.8% | ||
| Q4 24 | 41.6% | 69.0% | ||
| Q3 24 | 41.1% | 68.7% | ||
| Q2 24 | 44.3% | 67.8% | ||
| Q1 24 | 43.1% | 67.5% |
营业利润率EPCOFIX
| Q4 25 | -4.5% | 0.2% | ||
| Q3 25 | -4.2% | -8.3% | ||
| Q2 25 | 8.6% | -7.9% | ||
| Q1 25 | 10.1% | -25.2% | ||
| Q4 24 | 2.2% | -5.3% | ||
| Q3 24 | 3.9% | -9.6% | ||
| Q2 24 | 12.8% | -12.5% | ||
| Q1 24 | 11.7% | -15.6% |
净利率EPCOFIX
| Q4 25 | -15.5% | -1.0% | ||
| Q3 25 | -5.1% | -11.1% | ||
| Q2 25 | 4.6% | -6.9% | ||
| Q1 25 | 5.0% | -27.4% | ||
| Q4 24 | -0.5% | -13.5% | ||
| Q3 24 | 1.7% | -13.9% | ||
| Q2 24 | 7.6% | -16.8% | ||
| Q1 24 | 6.0% | -19.1% |
每股收益（稀释后）EPCOFIX
| Q4 25 | $-1.41 | $-0.05 | ||
| Q3 25 | $-0.65 | $-0.57 | ||
| Q2 25 | $0.62 | $-0.36 | ||
| Q1 25 | $0.60 | $-1.35 | ||
| Q4 24 | $-0.04 | $-0.76 | ||
| Q3 24 | $0.18 | $-0.71 | ||
| Q2 24 | $0.98 | $-0.88 | ||
| Q1 24 | $0.72 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $82.0M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $1.5B | $450.0M |
| 总资产 | $3.8B | $850.6M |
| 负债/权益比越低杠杆越低 | 1.03× | — |
8季度趋势，按日历期对齐
现金及短期投资EPCOFIX
| Q4 25 | — | $82.0M | ||
| Q3 25 | — | $62.9M | ||
| Q2 25 | — | $65.6M | ||
| Q1 25 | — | $58.0M | ||
| Q4 24 | — | $83.2M | ||
| Q3 24 | $209.1M | $30.1M | ||
| Q2 24 | — | $26.4M | ||
| Q1 24 | — | $27.0M |
总债务EPCOFIX
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | $157.2M | ||
| Q2 25 | $1.4B | $157.0M | ||
| Q1 25 | $1.4B | $156.9M | ||
| Q4 24 | $1.4B | $157.0M | ||
| Q3 24 | $1.3B | $118.5M | ||
| Q2 24 | $1.3B | $118.0M | ||
| Q1 24 | $1.4B | $118.2M |
股东权益EPCOFIX
| Q4 25 | $1.5B | $450.0M | ||
| Q3 25 | $1.6B | $442.5M | ||
| Q2 25 | $1.6B | $458.3M | ||
| Q1 25 | $1.5B | $458.3M | ||
| Q4 24 | $1.5B | $503.1M | ||
| Q3 24 | $1.6B | $525.9M | ||
| Q2 24 | $1.6B | $546.0M | ||
| Q1 24 | $1.6B | $570.3M |
总资产EPCOFIX
| Q4 25 | $3.8B | $850.6M | ||
| Q3 25 | $3.8B | $832.6M | ||
| Q2 25 | $3.8B | $837.2M | ||
| Q1 25 | $3.8B | $823.1M | ||
| Q4 24 | $3.7B | $893.3M | ||
| Q3 24 | $3.7B | $867.9M | ||
| Q2 24 | $3.7B | $882.0M | ||
| Q1 24 | $3.8B | $906.0M |
负债/权益比EPCOFIX
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.89× | 0.36× | ||
| Q2 25 | 0.88× | 0.34× | ||
| Q1 25 | 0.95× | 0.34× | ||
| Q4 24 | 0.97× | 0.31× | ||
| Q3 24 | 0.81× | 0.23× | ||
| Q2 24 | 0.82× | 0.22× | ||
| Q1 24 | 0.88× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-125.9M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-137.5M | $16.8M |
| 自由现金流率自由现金流/营收 | -32.5% | 7.6% |
| 资本支出强度资本支出/营收 | 2.7% | 4.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $36.3M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流EPCOFIX
| Q4 25 | $-125.9M | $27.7M | ||
| Q3 25 | $74.1M | $12.4M | ||
| Q2 25 | $114.8M | $11.6M | ||
| Q1 25 | $45.1M | $-18.4M | ||
| Q4 24 | $-115.6M | $23.7M | ||
| Q3 24 | $-388.3M | $11.7M | ||
| Q2 24 | $101.2M | $9.0M | ||
| Q1 24 | $129.0M | $-18.6M |
自由现金流EPCOFIX
| Q4 25 | $-137.5M | $16.8M | ||
| Q3 25 | $46.5M | $2.5M | ||
| Q2 25 | $99.3M | $4.5M | ||
| Q1 25 | $28.0M | $-25.1M | ||
| Q4 24 | $-132.4M | $15.2M | ||
| Q3 24 | $-414.2M | $6.3M | ||
| Q2 24 | $88.6M | $-360.0K | ||
| Q1 24 | $117.5M | $-29.1M |
自由现金流率EPCOFIX
| Q4 25 | -32.5% | 7.6% | ||
| Q3 25 | 7.7% | 1.2% | ||
| Q2 25 | 15.8% | 2.2% | ||
| Q1 25 | 4.8% | -13.0% | ||
| Q4 24 | -31.9% | 7.0% | ||
| Q3 24 | -80.0% | 3.2% | ||
| Q2 24 | 13.7% | -0.2% | ||
| Q1 24 | 19.6% | -15.4% |
资本支出强度EPCOFIX
| Q4 25 | 2.7% | 4.9% | ||
| Q3 25 | 4.6% | 4.8% | ||
| Q2 25 | 2.5% | 3.5% | ||
| Q1 25 | 2.9% | 3.5% | ||
| Q4 24 | 4.0% | 4.0% | ||
| Q3 24 | 5.0% | 2.7% | ||
| Q2 24 | 1.9% | 4.7% | ||
| Q1 24 | 1.9% | 5.6% |
现金转化率EPCOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.95× | — | ||
| Q1 25 | 1.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.13× | — | ||
| Q2 24 | 2.07× | — | ||
| Q1 24 | 3.58× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
